Research Paper Volume 10, Issue 10 pp 2741—2754
A single-nucleotide polymorphism (rs1805087) in the methionine synthase (METH) gene increases the risk of prostate cancer
- 1 Department of Urology, Nantong Tongzhou District People’s Hospital, Nantong 226300, China
- 2 Department of Orthopedics, Qidong People’s Hospital, Nantong 226200, China
- 3 Department of Clinical Pharmacy, the Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400, China
- 4 Department of Orthopedics, the Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400, China
received: July 6, 2018 ; accepted: September 26, 2018 ; published: October 18, 2018 ;https://doi.org/10.18632/aging.101584
How to Cite
Copyright: Zhang et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Methionine synthase (METH, i.e., MTR) is a key enzyme in the folate pathway, which plays a critical role in the synthesis, repair, and methylation of DNA. The association between METH gene polymorphisms and prostate cancer susceptibility remains ambiguous. Thus, we performed an updated meta-analysis of METH single-nucleotide polymorphism rs1805087 involving 12 independent case-control studies comprising 9986 prostate cancer patients and 40134 controls. The odds ratio and 95% confidence intervals were applied to evaluate the relation of this single-nucleotide polymorphism with prostate cancer. Statistical analysis was performed in STATA 11.0. A significant association was found between rs1805087 and increased prostate cancer risk, overall and with Hardy–Weinberg equilibrium. In subgroup analyses (based on ethnicity, source of control, genotyping methods, or publication status), similar associations were observed (e.g., genotype GA vs. AA: odds ratio 1.19, 95% confidence interval 1.01–1.40 among whites; G allele vs. A allele: odds ratio 1.14, 95% confidence interval 1.02–1.28 among hospital-based controls). Thus, the common polymorphism (rs1805087) of METH may be associated with increased prostate cancer risk. Further studies with a larger sample size and detailed gene–environment interactions should be conducted to identify the role of METH polymorphisms in prostate cancer susceptibility.
Prostate cancer (PCa) is a leading cause of cancer-associated deaths among men in developed countries . Although the incidence of PCa is much lower in the Asian population than in its western counterpart, in recent years, the incidence of PCa and the PCa mortality rate in some Asian countries grew rapidly [2,3]. Age, a positive family history, African-American origin, alcohol use, and certain gene mutations are significant risk factors of PCa [4,5]. Particularly, genetic factors play a prominent role in the pathogenesis of PCa. For example, Lynch syndrome (germline mutations in MLH1, MSH2, MSH6, PMS2, or EPCAM) increases the risk of PCa two- to fivefold, in comparison with the general population [4,6–8].
Folate metabolism–associated genes involved in both DNA methylation and repair are thought to play an important part in tumorigenesis . The gene encoding methionine synthase (METH, i.e., MTR), a key enzyme in the folate pathway, is located on human chromosome 1 (1q43) [10,11]. Encoded by 34 exons, the METH protein is 1265 amino acid residues long, with a molecular weight of 140.5 kDa . A common polymorphism in METH has been found at position 2756 (METH A2756G; rs1805087) . This polymorphism may promote homocysteine upregulation and DNA methylation, thereby increasing the enzymatic activity of METH . Moreover, this polymorphism may result in CpG island hypermethylation in tumor suppressor genes, such as TP53 .
Some studies that have addressed the effects of the METH rs1805087 single-nucleotide polymorphism (SNP) on the risk of PCa have yielded inconsistent results. Collin et al. (2009)  investigated the effect of eight SNPs, including MTHFR rs1801133, MTHFR rs1801131, METH rs1805087, METHR rs1801394, MTHFD1 rs2236225, SLC19A1/RFC1 rs1051266, SHMT1 rs1979277, and FOLH1 rs202676, on PCa risk in a meta-analysis and found no significant effects of any of these SNPs on PCa susceptibility. The study included eight case-control studies (five of which have not been published) on rs1805087. Since 2009, many more original research articles have been published, making it necessary to combine the data from all the aforementioned studies and reanalyze the association between rs1805087 and PCa susceptibility.
The objective of our study was to examine associations between rs1805087 genotypes and the risk of PCa in larger samples by meta-analysis (9986 PCa patients and 40134 controls from 12 studies) [16–27].
Using different combinations of key terms, 24 studies were identified in PubMed and Embase. As shown in Figure 1, seven duplicate studies were excluded. Among the remaining 17 studies, five were excluded: one about the upper gastrointestinal tract , one meta-analysis , one abstract , one involving TNM or Gleason scores , but lacking genotype frequencies of cases/controls, and one missing the available genotype frequencies . We also included the study by Collin et al. (2009), which contains findings from five unpublished studies [16,17,19,22,24,26].
Figure 1. A flowchart illustrating the search strategy used to identify studies on association of METH SNP rs1805087 with PCa risk.
Finally, we identified 12 case-control studies [16–27], involving 9986 PCa patients and 40134 controls regarding rs1805087 to evaluate its association with PCa risk (Table 1). The power of our analysis was 0.213. The distribution of genotypes among controls was consistent with the HWE in all studies except two [16,19]. The control population in all the included studies consisted of age-matched men as study participants with a normal digital rectal examination profile and serum prostate-specific antigen (PSA) values <4 ng/ml, without a known history of cancer (personal or familial). To examine representativeness of our analysis, we investigated the minor allele frequency (MAF) reported for the five main worldwide populations in the 1000 Genomes Browser: East Asian, 0.105; European, 0.173; African, 0.284; American, 0.177; and South Asian: 0.321 (Figure 2). In the same interval of the 1000 Genomes Browser database, MAFs in our analyses were 0.183 and 0.178 in the case group and control group, respectively (https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1805087). The various genotyping methods employed in the analyzed studies included polymerase chain reaction with restriction fragment length polymorphism (PCR-FLIP), sequencing, TaqMan, GeneChip, Illumina, and SNaPshot analyses [16–27].
Table 1. Basic information for included studies of the association between METH rs1805087 polymorphism sites and prostate cancer susceptibility.
|ProtecT||2008||UK||Caucasian||1600||2076||Unpublished||PB||52||515||1033||84||637||1355||0.402||allele-specific PCR (KASPar) and Taqman||7|
|HWE: Hardy–Weinberg equilibrium; HB: hospital-based; PB: population-based; PCR-FLIP: polymerase chain reaction and restrictive fragment length polymorphism, NOS: Newcastle-Ottawa Scale|
The overall meta-analysis results suggested significant associations between two rs1805087 genotypes and increased PCa susceptibility for all genetic models (e.g., homozygote comparison: OR = 1.15, 95% CI 1.00–1.32, Pheterogeneity = 0.263, P = 0.048; dominant model: OR = 1.20, 95% CI 1.05–1.38, Pheterogeneity = 0.000, P = 0.009; allelic comparison: OR = 1.15, 95% CI 1.04–1.29, Pheterogeneity = 0.000, P = 0.008; Figure 3; heterozygote comparison: OR = 1.20, 95% CI 1.04–1.38, Pheterogeneity = 0.000, P = 0.012; Table 2). After exclusion of the two studies where the data did not obey the HWE, the overall observed association did not change (Table 2), indicating that our analysis was powerful, stable, and representative.
Figure 3. An overall forest plot of PCa risk associated with rs1805087 (G allele vs. A allele). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of variance). The diamond represents the summary OR and 95% CI.
Table 2. Total and stratified subgroup analysis for METH rs1805087 polymorphism sites and prostate cancer susceptibility.
|Variables||N||Case/||G-allele vs. A-allele||GA vs. AA||GG vs. AA||GG+GA vs. AA|
|Control||OR(95%CI) PhP||OR(95%CI) PhP||OR(95%CI) PhP||OR(95%CI) PhP|
|Total||12||9986/40134||1.15(1.04-1.29)0.000 0.008||1.20(1.04-1.38)0.000 0.012||1.15(1.00-1.32)0.263 0.048||1.20(1.05-1.38)0.000 0.009|
|With HWE||10||9088/38909||1.08(1.00-1.17)0.074 0.040||1.07(1.01-1.14)0.160 0.027||1.11(0.96-1.29)0.252 0.154||1.10(1.00-1.20)0.080 0.039|
|Asian||3||2134/2346||1.33(0.94-1.88)0.050 0.109||1.31(0.84-2.05)0.044 0.233||1.93(1.14-3.26)0.390 0.014||1.38(0.87-2.20)0.024 0.174|
|Caucasian||9||7852/37788||1.12(1.00-1.27)0.000 0.052||1.19(1.01-1.40)0.000 0.043||1.10(0.95-1.28)0.462 0.181||1.18(1.01-1.38)0.000 0.042|
|Source of Control|
|HB||6||2857/3066||1.14(1.02-1.28)0.144 0.017||1.16(1.02-1.31)0.265 0.028||1.28(0.89-1.82)0.232 0.181||1.16(1.03-1.32)0.145 0.018|
|PB||6||7129/37068||1.16(1.00-1.34)0.000 0.053||1.22(0.99-1.50)0.000 0.067||1.13(0.97-1.32)0.275 0.116||1.22(1.00-1.48)0.000 0.054|
|Others||2||1989/2257||1.14(0.99-1.31)0.747 0.069||1.13(0.96-1.32)0.931 0.135||1.37(0.79-2.40)0.582 0.265||1.14(0.98-1.33)0.865 0.090|
|Taqman||4||2945/3670||1.14(0.87-1.49)0.000 0.333||1.29(0.90-1.84)0.000 0.172||0.98(0.77-1.25)0.183 0.857||1.24(0.87-1.77)0.000 0.235|
|PCR-RFLP||2||317/320||1.49(0.81-2.74)0.058 0.202||1.50(0.60-3.73)0.026 0.385||2.78(1.19-6.50)0.404 0.018||1.61(0.65-3.99)0.020 0.307|
|Sequencing||4||4735/33887||1.09(0.97-1.23)0.056 0.162||1.05(0.97-1.13)0.101 0.240||1.19(0.99-1.43)0.676 0.070||1.09(0.95-1.25)0.061 0.217|
|Published||7||3583/4050||1.29(1.06-1.58)0.003 0.012||1.38(1.04-1.83)0.000 0.024||1.38(1.05-1.83)0.278 0.023||1.39(1.06-1.82)0.000 0.017|
|Unpublished||5||6403/36084||1.05(0.99-1.11)0.241 0.111||1.05(0.98-1.12)0.288 0.161||1.08(0.92-1.27)0.415 0.339||1.05(0.99-1.12)0.249 0.120|
|Ph: value of Q-test for heterogeneity test; P: Z-test for the statistical significance of the OR; HWE: Hardy–Weinberg equilibrium; HB: hospital-based; PB: population-based; PCR-FLIP: polymerase chain reaction and restrictive fragment length polymorphism.|
Next, we stratified the studies by ethnicity. We found that there was a similar relation between two rs1805087 genotypes and PCa susceptibility among both Asians and whites (whites: genotype GA vs. AA: OR = 1.19, 95% CI 1.01–1.40, Pheterogeneity = 0.000, P = 0.043; Figure 4; GG+GA vs. AA: OR = 1.18, 95% CI 1.01–1.38, Pheterogeneity = 0.000, P = 0.042, Asians: GG vs. AA: OR = 1.93, 95% CI 1.14–3.26, Pheterogeneity = 0.390, P = 0.014; Figure 5; Table 2).
Figure 4. A forest plot of PCa risk associated with rs1805087 among whites (genotype GA vs. AA). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of variance). The diamond represents the summary OR and 95% CI.
Figure 5. A forest plot of PCa risk associated with rs1805087 among Asians (genotype GG vs. AA). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of variance). The diamond represents the summary OR and 95% CI.
In the stratified analysis of the source of the control subgroup, significant associations were found among hospital-based controls (e.g.: G-allele vs. A-allele: OR = 1.14, 95% CI 1.02–1.28, Pheterogeneity = 0.144, P = 0.017; genotype GA vs. AA: OR = 1.16, 95% CI 1.02–1.31, Pheterogeneity = 0.265, P = 0.028 and GG+GA vs. AA: OR = 1.16, 95% CI 1.03–1.32, Pheterogeneity = 0.145, P = 0.018) but not among population-based controls (Table 2).
Because several genotyping methods were involved, we also analyzed the genotype method subgroup. In this subgroup, we observed a significant association between rs1805087 and increased PCa susceptibility only according to the PCR-RFLP method (GG vs. AA: OR = 2.78, 95% CI 1.19–6.50, Pheterogeneity = 0.404, P = 0.018; Figure 6; Table 2).
Figure 6. A forest plot of PCa risk associated with rs1805087 in terms of genotype methods (GG vs. AA). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of variance). The diamond represents the summary OR and 95% CI.
Finally, because five unpublished studies were included, we examined the publication status subgroup. Compared to the unpublished studies, significant associations between rs1805087 genotypes and increased PCa susceptibility were found in published studies (e.g., GG+GA vs. AA: OR = 1.39, 95% CI 1.06–1.82, Pheterogeneity = 0.000, P = 0.017; Figure 7; Table 2).
Figure 7. A forest plot of PCa risk associated with rs1805087 in terms of publication status (genotypes GG+GA vs. AA). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of variance). The diamond represents the summary OR and 95% CI.
Sensitivity analysis and bias detection
We next performed a sensitivity analysis on two studies [20,24], where the controls did not conform to the HWE, to determine the effect of excluded specific studies. In addition, the sensitivity analysis was carried out to determine whether modification of the inclusion criteria of the meta-analysis affected the results. According to our sensitivity analysis, no other single study (including the two studies described above) influenced the summary OR qualitatively (Figure 8). Begg’s funnel plot analysis and Egger’s test were performed to assess the literature publication bias. The shape of the Begg’s funnel plot did not reveal any obvious asymmetry, and Egger’s test ruled out any publication bias (e.g., G allele vs. A-allele: T allele vs. C allele, t = 1.38, P = 0.196 in Egger’s test; and z = 1.03, P = 0.304 in Begg’s test; Table 3, Figure 9).
Table 3. Publication bias tests (Begg’s funnel plot and Egger’s test for publication bias test) for METH rs1805087 polymorphism.
|Egger's test||Begg's test|
|Genetic type||Coefficient||Standard error||t||P value||95%CI of intercept||z||P value|
|G-allele vs. A-allele||1.465739||1.059131||1.38||0.196||0.8941511- 3.825629||1.03||0.304|
|GA vs. AA||1.174084||0.8164867||1.4||0.181||0.6451616-2.99333||1.17||0.244|
|GG vs. AA||0.521603||0.3957242||1.32||0.217||0.3601251-1.403332||1.03||0.304|
|GG+GA vs. AA||1.25699||0.8545912||1.47||0.172||0.6471578- 3.161138||1.17||0.244|
|GG vs. GA+AA||0.524554||0.4058054||1.29||0.225||0.379637- 1.428745||1.03||0.304|
Figure 9. Begg’s funnel plot for publication bias testing in analyses involving association of rs1805087 with PCa risk. (a: G allele vs. A allele; b: genotype GA vs. AA; c: GG vs. AA; d: GG+GA vs. AA). Each point represents a separate study on the indicated association. Log [OR] stands for the natural logarithm of OR. The horizontal line indicates mean effect size. b: Egger’s publication bias plot of rs1805087 and PCa risk (e: G allele vs. A allele; f: genotype GA vs. AA; g: GG vs. AA; h: GG+GA vs. AA).
Identification of SNPs that affect gene expression or function and contribute to cancer susceptibility helps to predict individual and population risks as well as to understand the pathogenesis of cancer . Owing to its deep involvement in cancer development, the METH rs1805087 SNP in several types of cancers has been widely studied: breast cancer, head and neck carcinoma, lung cancer, pancreatic cancer, gastrointestinal cancer, non-Hodgkin lymphoma, and ovarian cancer, to name a few [33–37]. No significant association has been detected between rs1805087 and any cancer types mentioned above.
Kimura et al.  were the first to report an association between rs1805087 and increased PCa risk. Nonetheless, the allele distribution of rs1805087 did not differ among PCa patients stratified by age, clinical stage, or the presence of metastases. To our knowledge, sites with altered DNA methylation are found in many human cancers, including those prevalent in PCa. The enzymes methylenetetrahydrofolate reductase (MTHFR), METH, METH reductase (METHR), and thymidylate synthase perform essential functions in folate metabolism: an important source of materials for DNA and RNA synthesis and methylation. The remethylation of homocysteine to methionine is catalyzed by METH in a vitamin B12–dependent reaction (B12 acts as an intermediary carrier of a methyl group). METH becomes inactive upon oxidation of the remethylation cofactor (vitamin B12) by METHR. The latter catalyzes the regeneration of methylcobalamin, a METH cofactor, important for keeping METH active [38,39]. Rs1805087, one of the valuable SNPs in relation to PCa risk, may increase METH expression and indirectly participate in DNA methylation and the folate metabolic pathway. Subsequently, several investigators have confirmed these findings in larger samples and different populations [18,23,25]. Nonetheless, the lack of systematic and cohesive analysis renders these results ambiguous, even within the same population.
Meta-analysis is a means of increasing the effective sample size by pooling data from association studies, thereby enhancing the statistical power of estimation of genetic effects . In 2009, Collin et al.  reported the first relevant meta-analysis, which included eight case-control studies (five were unpublished studies) and found no association between rs1805087 and PCa risk in all genetic models. By contrast, a significant association was observed between rs1805087 in localized increased PCa susceptibility (dominant model comparison, OR = 1.16, 95% CI 1.04–1.29, P = 0.008). A growing number of original research articles and unpublished studies makes it necessary to combine data from all the studies to date and to reanalyze the association between rs1805087 and PCa risk.
In this study, we analyzed the associations between genotypes of rs1805087 and PCa risk by the meta-analysis method to reach a statistically backed conclusion. The potential ability of rs1805087 to increase PCa risk was investigated in a sample of 9986 cases and 40134 controls from seven published and five unpublished case-control studies. The conclusions from our results are 1) individuals who carry the rs1805087 G allele have increased susceptibility to PCa; 2) rs1805087 may increase PCa risk among both Asians and whites. These conclusions are reported for the first time and warrant continuation of research into rs1805087 regarding other types of cancer.
Of the 12 studies, excluding the five unpublished studies [16,17,19,22,26], six detected no significant association between rs1805087 and PCa risk. Only one study  indicates that the AG genotype, GG genotype, and G allele are associated with higher PCa risk. Nonetheless, in our meta-analysis of risk estimates, when all the studies were pooled, we obtained evidence for a significant association between rs1805087 and higher PCa risk. This finding can be explained as follows: first, the etiology of PCa is complicated, involving gene–gene and gene–environment (including gene–nutrition) interactions. Therefore, the environmental (including nutritional) factors cannot be ignored. Future studies that combine other genes from folic acid and methionine metabolic pathways with METH are needed for accurate analysis and interpretation. Furthermore, if the number of included studies had not been large, false negative results may have been obtained about this SNP. Thus, further studies should have a larger sample size. It would be beneficial to use meta-analysis to obtain more accurate results.
Although we made considerable efforts and devoted substantial resources to testing the possible association between rs1805087 and PCa risk, there are some limitations inherent in the included studies. First, despite inclusion of all the eligible studies, the resultant sample size is still not large enough [20,27]; this situation may increase the likelihood of type I and type II errors. Second, the literature review was primarily based on PubMed and Embase databases. Thus, some publications may be missing, thereby causing some bias in risk estimates. Third, the lack of original data, such as age, gender, the body–mass index, diet, alcohol consumption, smoking status, and a family history of cancer, limited our ability to further evaluate the adjusted OR and gene–environment interactions. Therefore, it is necessary to evaluate the roles of some special environmental factors, including lifestyles. Fourth, moderate heterogeneity was observed in overall comparisons and several subgroups; this heterogeneity could result from small sample sizes and from differential effects of the analyzed SNP in different ethnic groups involved. Fifth, we included five unpublished studies from Collin et al. (2009). The limitations of using unpublished studies are a) frequencies in these studies are not strictly evaluated by a peer review process, and b) the results of these studies may confuse the results of published studies. Besides, we included all the published and unpublished studies in our current analysis to show that this is a comprehensive meta-analysis and may yield powerful and objective conclusions. The data of these five unpublished studies all came from a published study (Collin et al., 2009) and therefore were not unpublished strictly speaking and may be considered a valid source and can increase the credibility of conclusions.
In summary, our meta-analysis shows that METH SNP rs1805087 may increase susceptibility to PCa. Further well-designed studies with a large sample size, different ethnicities, and detailed environmental factors are needed to validate the conclusions of our meta-analysis.
Materials and Methods
The search strategy
We searched the PubMed and Embase databases for all articles on the association between rs1805087 and PCa risk up to January 20, 2018. The medical subject headings and key words used for the search were “MTR or methionine synthase,” and “prostate cancer or carcinoma,” and “polymorphism or variant.” The electronic search also covered the reference lists of all the identified articles and reviews to find possible additional original reports. All the included studies met the following criteria: (1) the design was “case-control study,” (2) the association between rs1805087 and PCa risk was explored (both published and unpublished), and (3) carcinoma cases were diagnosed histopathologically. The major exclusion criteria were (1) duplicate data; (2) abstract only, commentary, review, or editorial publications; and (3) insufficient reporting of data.
The following information was collected: the first author’s last name, year of publication, country of origin, ethnicity, source of the control (hospital-based or population-based) and the Hardy–Weinberg equilibrium (HWE) of the control, total number of cases/controls, and genotyping method. Subgroups were classified based on the source of the control, on ethnicity, genotyping method, and publication status.
Quality score assessment
The Newcastle-Ottawa Scale (NOS)  was selected to assess the quality of each study. This measure assesses aspects of the methodologies used in observational studies, which are related to the study quality, including selection of cases, comparability of populations, and ascertainment of exposure to risks. The NOS rating ranges from zero stars (worst) to nine stars (best). Studies with a score of seven stars or greater was considered as a high quality.
The strength of the association between rs1805087 and PCa risk was measured by odds ratios (ORs) with 95% confidence intervals (CIs). Pooled ORs were obtained from a combination of studies by heterozygote comparison, homozygote comparison, dominant and recessive models, and allelic comparison. Heterogeneity among the studies was checked using the χ2-based Q statistic and was considered statistically significant at P < 0.10 . At P > 0.10, the pooled OR of each study was calculated via the fixed-effects model (the Mantel–Haenszel method, which weights the studies by the inverse of the variance of estimates). Otherwise, the random-effects model (the DerSimonian and Laird method) was used [43,44]. The significance of the pooled OR was determined by the Z-test, and data with P < 0.05 were considered statistically significant. The departure of frequencies of rs1805087 from the expected values under the HWE was assessed by the χ2 test among controls; P < 0.05 was assumed to denote a significant disequilibrium. Publication bias was detected with Egger’s linear regression method and funnel plot; the funnel plot asymmetry was assessed by Begg’s test; data with P < 0.05 were considered statistically significant . All statistical tests in this meta-analysis were two-sided and performed in the STATA software, version 10.0 (STATA Corp., College Station, TX, USA). The power of our meta-analysis was calculated by means of software called PS: Power and Sample Size Calculation (http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize#Windows) .
Conflicts of Interest
The authors have no conflicts of interest to declare.
This work was supported by the National Natural Science Foundation (81501874) and Jiangsu Province Health and Family Planning Commission Foundation (Q201511 and QNRC2016139).
- 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86. https://doi.org/10.1002/ijc.29210 [PubMed]
- 2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61:1079–92. https://doi.org/10.1016/j.eururo.2012.02.054 [PubMed]
- 3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86. https://doi.org/10.1002/ijc.29210 [PubMed]
- 4. Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM. Prostate cancer incidence in males with Lynch syndrome. Genet Med. 2014; 16:553–57. https://doi.org/10.1038/gim.2013.193 [PubMed]
- 5. Stewart RW, Lizama S, Peairs K, Sateia HF, Choi Y. Screening for prostate cancer. Semin Oncol. 2017; 44:47–56. https://doi.org/10.1053/j.seminoncol.2017.02.001 [PubMed]
- 6. Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel Doeberitz M, Goecke TO, Schmiegel W, Buettner R, Moeslein G, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 2012; 30:4409–15. https://doi.org/10.1200/JCO.2012.43.2278 [PubMed]
- 7. Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, Syngal S, Cooney KA, Gruber SB. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol. 2013; 31:1713–18. https://doi.org/10.1200/JCO.2012.44.1238 [PubMed]
- 8. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014; 23:437–49. https://doi.org/10.1158/1055-9965.EPI-13-1165 [PubMed]
- 9. Kim KC, Friso S, Choi SW. DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. J Nutr Biochem. 2009; 20:917–26. https://doi.org/10.1016/j.jnutbio.2009.06.008 [PubMed]
- 10. Karimian M, Hosseinzadeh Colagar A. Methionine synthase A2756G transition might be a risk factor for male infertility: evidences from seven case-control studies. Mol Cell Endocrinol. 2016; 425:1–10. https://doi.org/10.1016/j.mce.2016.02.012 [PubMed]
- 11. Chen LH, Liu ML, Hwang HY, Chen LS, Korenberg J, Shane B. Human methionine synthase. cDNA cloning, gene localization, and expression. J Biol Chem. 1997; 272:3628–34. https://doi.org/10.1074/jbc.272.6.3628 [PubMed]
- 12. Goulding CW, Postigo D, Matthews RG. Cobalamin-dependent methionine synthase is a modular protein with distinct regions for binding homocysteine, methyltetrahydrofolate, cobalamin, and adenosylmethionine. Biochemistry. 1997; 36:8082–91. https://doi.org/10.1021/bi9705164 [PubMed]
- 13. Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, Heng HH, Rommens JM, Scherer SW, Rosenblatt DS, Gravel RA. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA. 1998; 95:3059–64. https://doi.org/10.1073/pnas.95.6.3059 [PubMed]
- 14. Goode EL, Potter JD, Bigler J, Ulrich CM. Methionine synthase D919G polymorphism, folate metabolism, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2004; 13:157–62. https://doi.org/10.1158/1055-9965.EPI-03-0097 [PubMed]
- 15. Paz MF, Avila S, Fraga MF, Pollan M, Capella G, Peinado MA, Sanchez-Cespedes M, Herman JG, Esteller M. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res. 2002; 62:4519–24. [PubMed]
- 16. Collin SM, Metcalfe C, Zuccolo L, Lewis SJ, Chen L, Cox A, Davis M, Lane JA, Donovan J, Smith GD, Neal DE, Hamdy FC, Gudmundsson J, et al, and UK Genetic Prostate Cancer Study Group. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009; 18:2528–39. https://doi.org/10.1158/1055-9965.EPI-09-0223 [PubMed]
- 17. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006; 38:652–58. https://doi.org/10.1038/ng1808 [PubMed]
- 18. Cai D, Ning L, Pan C, Liu X, Bu R, Chen X, Wang K, Cheng Y, Wu B. Association of polymorphisms in folate metabolic genes and prostate cancer risk: a case-control study in a Chinese population. J Genet. 2010; 89:263–67. https://doi.org/10.1007/s12041-010-0037-7 [PubMed]
- 19. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, et al, and UK Genetic Prostate Cancer Study Collaborators, and British Association of Urological Surgeons’ Section of Oncology, and UK ProtecT Study Collaborators. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008; 40:316–21. https://doi.org/10.1038/ng.90 [PubMed]
- 20. López-Cortés A, Jaramillo-Koupermann G, Muñoz MJ, Cabrera A, Echeverría C, Rosales F, Vivar N, Paz-y-Miño C. Genetic polymorphisms in MTHFR (C677T, A1298C), MTR (A2756G) and MTRR (A66G) genes associated with pathological characteristics of prostate cancer in the Ecuadorian population. Am J Med Sci. 2013; 346:447–54. https://doi.org/10.1097/MAJ.0b013e3182882578 [PubMed]
- 21. Marchal C, Redondo M, Reyes-Engel A, Perea-Milla E, Gaitan MJ, Machuca J, Diaz F, Caballero J, Carnero J. Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer. Eur J Surg Oncol. 2008; 34:805–10. https://doi.org/10.1016/j.ejso.2007.09.008 [PubMed]
- 22. Murabito JM, Rosenberg CL, Finger D, Kreger BE, Levy D, Splansky GL, Antman K, Hwang SJ. A genome-wide association study of breast and prostate cancer in the NHLBI’s Framingham Heart Study. BMC Med Genet. 2007 (Suppl 1); 8:S6. https://doi.org/10.1186/1471-2350-8-S1-S6 [PubMed]
- 23. Qu YY, Zhou SX, Zhang X, Zhao R, Gu CY, Chang K, Yang XQ, Gan HL, Dai B, Zhang HL, Shi GH, Zhu Y, Ye DW, Zhao JY. Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: results from an ethnic Han Chinese population. Sci Rep. 2016; 6:36264. https://doi.org/10.1038/srep36264 [PubMed]
- 24. Stevens VL, Rodriguez C, Sun J, Talbot JT, Thun MJ, Calle EE. No association of single nucleotide polymorphisms in one-carbon metabolism genes with prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2008; 17:3612–14. https://doi.org/10.1158/1055-9965.EPI-08-0789 [PubMed]
- 25. Weiner AS, Oskina NA, Lacarev AF, Petrova VD, Ganov DI, Boyarskih UA, Tonacheva OG, Voronina EN, Filipenko ML. Role of polymorphic variants of MTR gene A2756G and SHMT1 gene C1420T in the development of prostatic cancer in residents of the Western Siberian Region of Russia. Bull Exp Biol Med. 2012; 152:466–69. https://doi.org/10.1007/s10517-012-1554-6 [PubMed]
- 26. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007; 39:645–49. https://doi.org/10.1038/ng2022 [PubMed]
- 27. Ebrahimi A, Hosseinzadeh Colagar A, Karimian M. Association of Human Methionine Synthase-A2756G Transition With Prostate Cancer: A Case-Control Study and in Silico Analysis. Acta Med Iran. 2017; 55:297–303. [PubMed]
- 28. Ott N, Geddert H, Sarbia M. Polymorphisms in methionine synthase (A2756G) and cystathionine beta-synthase (844ins68) and susceptibility to carcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 2008; 134:405–10. https://doi.org/10.1007/s00432-007-0301-2 [PubMed]
- 29. Watanabe M, Hirokawa Y, Suzuki H, Ichikawa T, Katoh T, Sugimura Y, Shiraishi T. Genetic variations in the one-carbon transfer pathway and aberrant DNA methylation in prostate cancer. Cancer Res. 2010; 70:8 Suppl.1.
- 30. Kimura F, Franke KH, Steinhoff C, Golka K, Roemer HC, Anastasiadis AG, Schulz WA. Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. Prostate. 2000; 45:225–31. https://doi.org/10.1002/1097-0045(20001101)45:3<225::AID-PROS4>3.0.CO;2-7 [PubMed]
- 31. Jackson MD, Tulloch-Reid MK, McFarlane-Anderson N, Watson A, Seers V, Bennett FI, Egleston B, Ragin C. Complex interaction between serum folate levels and genetic polymorphisms in folate pathway genes: biomarkers of prostate cancer aggressiveness. Genes Nutr. 2013; 8:199–207. https://doi.org/10.1007/s12263-012-0321-7 [PubMed]
- 32. Mi Y, Zhang L, Feng N, Wu S, You X, Shao H, Dai F, Peng T, Qin F, Zou J, Zhu L. Impact of two common xeroderma pigmentosum group D (XPD) gene polymorphisms on risk of prostate cancer. PLoS One. 2012; 7:e44756. https://doi.org/10.1371/journal.pone.0044756 [PubMed]
- 33. Aksoy-Sagirli P, Erdenay A, Kaytan-Saglam E, Kizir A. Association of Three Single Nucleotide Polymorphisms in MTR and MTRR Genes with Lung Cancer in a Turkish Population. Genet Test Mol Biomarkers. 2017; 21:428–32. https://doi.org/10.1089/gtmb.2017.0062 [PubMed]
- 34. Chang SC, Chang PY, Butler B, Goldstein BY, Mu L, Cai L, You NC, Baecker A, Yu SZ, Heber D, Lu QY, Li L, Greenland S, Zhang ZF. Single nucleotide polymorphisms of one-carbon metabolism and cancers of the esophagus, stomach, and liver in a Chinese population. PLoS One. 2014; 9:e109235. https://doi.org/10.1371/journal.pone.0109235 [PubMed]
- 35. He J, Wang F, Zhu JH, Chen W, Cui Z, Jia WH. No association between MTR rs1805087 A > G polymorphism and non-Hodgkin lymphoma susceptibility: evidence from 11 486 subjects. Leuk Lymphoma. 2015; 56:763–67. https://doi.org/10.3109/10428194.2014.935370 [PubMed]
- 36. Lin W, Cen YL, Lin Y, Su FX, Wu BH, Tang LY, Ren ZF. Joint effects between urinary selenium and polymorphisms in methylation related genes on breast cancer risk. Neoplasma. 2015; 62:491–99. https://doi.org/10.4149/neo_2015_059 [PubMed]
- 37. Nakao H, Wakai K, Ishii N, Kobayashi Y, Ito K, Yoneda M, Mori M, Nojima M, Kimura Y, Endo T, Matsuyama M, Ishii H, Ueno M, et al. Associations between polymorphisms in folate-metabolizing genes and pancreatic cancer risk in Japanese subjects. BMC Gastroenterol. 2016; 16:83. https://doi.org/10.1186/s12876-016-0503-7 [PubMed]
- 38. Hubner RA, Muir KR, Liu JF, Sellick GS, Logan RF, Grainge M, Armitage N, Chau I, Houlston RS. Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence. Cancer Epidemiol Biomarkers Prev. 2006; 15:1607–13. https://doi.org/10.1158/1055-9965.EPI-06-0274 [PubMed]
- 39. Hobbs CA, Sherman SL, Yi P, Hopkins SE, Torfs CP, Hine RJ, Pogribna M, Rozen R, James SJ. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet. 2000; 67:623–30. https://doi.org/10.1086/303055 [PubMed]
- 40. Munafò MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004; 20:439–44. https://doi.org/10.1016/j.tig.2004.06.014 [PubMed]
- 41. Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 42. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539–58. https://doi.org/10.1002/sim.1186 [PubMed]
- 43. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177–88. https://doi.org/10.1016/0197-2456(86)90046-2 [PubMed]
- 44. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22:719–48. [PubMed]
- 45. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–34. https://doi.org/10.1136/bmj.315.7109.629 [PubMed]
Dupont WD, Plummer WD
Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998; 19:589–601. https://doi.org/10.1016/S0197-2456(98)00037-3 [PubMed]